Earnings Call Summary | Sanara MedTech(SMTI.US) Q3 2024 Earnings Conference
Earnings Call Summary | Sanara MedTech(SMTI.US) Q3 2024 Earnings Conference
The company experienced a net loss of $2.9 million in Q3 2024 due to higher SG&A costs, increased interest expenses, and expenses related to change in the fair value of earn-out liabilities.The following is a summary of the Sanara MedTech Inc. (SMTI) Q3 2024 Earnings Call Transcript:
以下是Sanara MedTech Inc. (SMTI) 2024年第三季度業績發佈會文本的摘要：
Financial Performance:
財務表現：
Sanara MedTech reported a Q3 2024 net revenue of $21.7 million, an increase of 35% year-over-year, marking its 12th consecutive record revenue quarter.
Adjusted EBITDA improved to $800,000 in Q3 2024 from $300,000 in Q3 2023.
The company experienced a net loss of $2.9 million in Q3 2024 due to higher SG&A costs, increased interest expenses, and expenses related to change in the fair value of earn-out liabilities.
Sanara MedTech報告2024年第三季度的淨營業收入爲$2170萬，同比增長35%，這是其連續第12個創紀錄營業收入季度。
調整後EBITDA從2023年第三季度的$300,000改善至2024年第三季度的$800,000。
由於SG&A成本上升、利息支出增加以及與實現負債公允價值變更相關的費用，公司在2024年第三季度經歷了$290萬的淨虧損。
Business Progress:
業務進展：
Continued strategic investment in THP technology for expected mid-2025 commercial launch.
Entered into a $5 million investment and exclusive U.S. distribution agreement with ChemoMouthpiece LLC, aligning well with Sanara's wound and skin care strategy.
Soft tissue product sales increased to $18.9 million and bone fusion products rose to $2.8 million in Q3 2024.
Surgical products now sold in over 1200 hospitals, with selling agreements expanding.
Strengthened R&D, focusing on CellerateRX.
繼續在THP科技方面進行戰略投資，預計在2025年中期進行商業化發佈。
與ChemoMouthpiece LLC簽署了$500萬的投資和獨家美國分銷協議，這與Sanara的創傷和皮膚護理策略非常契合。
軟組織產品銷量在2024年第三季度增長至1890萬美元，而骨融合產品上升至280萬美元。
外科產品現在在超過1200家醫院銷售，銷售協議正在擴大。
加強研發，專注於CellerateRX。
Opportunities:
機會：
Emphasized growth potential for non-acute wound care with THP value-based strategy set for mid-2025 launch.
Exploring mergers, acquisitions, and strategic partnerships to enhance surgical offerings and market reach.
強調非急性傷口護理的增長潛力，基於價值的THP策略計劃在2025中期推出。
探索併購和戰略合作伙伴關係，以增強外科產品和市場覆蓋率。
Risks:
風險：
Possible challenges in quickly achieving Profitability due to necessary ramp-up once Tissue Health Plus launches.
Dependency on strategic and financial partners for successful execution and scaling of operations.
一旦推出Tissue Health Plus，由於必要的產能提升，可能在迅速實現盈利方面面臨挑戰。
依賴於戰略和財務夥伴以成功執行和擴展業務。
More details: Sanara MedTech IR
更多詳情：Sanara MedTech 投資者關係
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：欲了解更全面的細節，請參閱IR網站。 文章僅供投資者參考，不構成任何指導或推薦建議。
譯文內容由第三人軟體翻譯。
